Gallium-68 Market Forecast to 2030 | Size, Share, Growth
市场洞察和分析师观点:
镓 68 是一种用于医疗诊断程序的正电子发射放射性同位素。它由锗 68/镓 68 (68Ge/68Ga) 发生器产生,半衰期为 68 分钟。前列腺癌和神经内分泌肿瘤患病率的增加以及核成像技术使用的激增是推动镓68市场增长的主要因素。然而,镓68的保质期短阻碍了市场的增长。此外,放射性示踪剂在癌症诊断中的使用预计将在未来几年带来新的镓 68 市场趋势。
增长动力:
前列腺癌和神经内分泌肿瘤患病率的增加Gallium-68 市场增长
前列腺癌和神经内分泌肿瘤的高患病率导致对正电子发射断层扫描 (PET) 诊断程序的需求增加。根据梅奥医学教育和研究基金会 (MFMER) 的说法,神经内分泌肿瘤是由神经内分泌细胞的恶性生长发展而来的。 Gallium-68 (Ga-68) 用于放射性诊断剂的放射性标记,通过 PET 定位成人和儿童的生长抑素受体阳性神经内分泌肿瘤。据英国癌症研究中心称,英国每年有超过 4,000 人被诊断患有神经内分泌肿瘤。约 50% 的神经内分泌肿瘤始于消化系统(胃、小肠和大肠、胰腺和直肠),约 20% 始于肺部。根据美国临床肿瘤学会 (ASCO) 的数据,美国每年有近 12,000 人被诊断患有神经内分泌肿瘤,估计有 171,000 人患有此诊断。
Ga-68 主要用于检测人体内的癌细胞。例如,Ga-68 PSMA-11 PET 扫描成像剂广泛用于检测前列腺癌细胞。根据世界癌症研究基金会 (WCRF) 国际报告,2020 年报告了超过 140 万例前列腺癌新病例。同样,根据国际癌症研究机构 (IARC),估计前列腺癌病例数从2022年的约147万增加到2030年的约183万,到2050年的约288万。因此,前列腺癌和神经内分泌肿瘤需要基于Ga-68的PET进行准确的医学诊断,这有助于提高肿瘤检出率并促进有效治疗规划。因此,这些情况的日益普遍,增强了镓 68 市场规模。
报告细分和范围:
镓 68 市场分析已进行通过考虑以下部分:应用程序和最终用户。根据应用,市场分为肿瘤学、神经学、心脏病学等。肿瘤学领域在 2022 年占据最大的 68 镓市场份额,预计在预测期内复合年增长率最高。肿瘤领域的市场细分为前列腺癌、神经内分泌肿瘤等。
按最终用户划分,市场分为医院、诊断和成像中心等。到 2022 年,医院细分市场将占据最大的镓 68 市场份额。此外,预计同一细分市场在预测期内的复合年增长率最高。
区域分析:
地理范围镓 68 市场报告包括北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。 2022年,北美占据最大的市场份额。混合成像等技术的进步、用于诊断和治疗的新型放射性药物的引入以及基于示踪剂原理的分子成像技术的发展极大地促进了美国核医学的进步。先进的医疗基础设施、前列腺癌发病率和患病率的上升以及主要参与者的产品创新进一步促进了北美 68 镓市场的扩张。根据国际癌症研究机构 (IARC) 的数据,美国癌症患者数量预计将从 2020 年的 228 万例增加到 2040 年的 312 万例。因此,癌症病例的增加预计将增加对核能的需求。成像,这有利于镓 68 市场的进步。
镓 68 市场,按应用划分 - 2022 年和 2030 年
行业发展和未来机遇:
一些战略发展(根据公司新闻稿)由在镓 68 市场运营的领先企业列出如下:
2023 年 12 月,Ariceum Therapeutics 的镓 68 (Ga-68) 获得美国和加拿大专利。 68) 放射性药物生产套件。该 IP 由 Theragnostics Ltd 开发,该公司于 2023 年被 Ariceum 收购。此前,Ga-68 放射性药物的生产涉及多步骤方法,这限制了随时可以生产的患者剂量数量。 Theragnostics 的 Ga-68 技术平台能够通过一个简单的步骤在一个小瓶中生产多剂量的 Ga-68 HBED-PSMA-11。 2023 年 3 月,Telix Pharmaceuticals 的补充新药申请获得 FDA 批准(sNDA) Illuccix(Ga-68 gozetotide 注射制剂试剂盒)用于筛查转移性前列腺癌患者,这些患者被推荐使用 Lutetium-177 PSMA 定向治疗。 2022 年 10 月,Telix 获得加拿大卫生部批准 Illuccix( Ga-68戈泽肽注射液制剂试剂盒)用于中危和高危前列腺癌的分期和再分期,以及复发性前列腺癌肿瘤组织的定位。 Illuccix 在使用 Ga-68 进行放射性标记后,建议与 PET 一起使用,以检测男性前列腺癌的 PSMA 阳性病变。 2021 年 9 月,Eckert & Ziegler Radiopharma GmbH 提交了对其药物主文件 (DMF) 的修订为 GalliaPharm 向美国 FDA 提交申请,从而将其 Gallium-68 发生器产品组合扩展到美国市场。该公司计划提供其获得专利的 Ge-68/Ga-68 发生器,容量高达 100 mCi,保质期为 12 个月或 700 次洗脱。 GalliaPharm 的 Ga-68 用于制备 PET 诊断成像药物。竞争格局和主要公司:
Novartis AG、Telix Pharmaceuticals (US) Inc、IRE-ELiT SA、ITM Medical Isotopes GmbH、Eckert & Ziegler Radiopharma GmbH、ARTMS Inc、IBA Radiopharma Solutions、Cardinal Health、Rosatom 和 Evergreen Theragnostics Inc 都是镓 68 市场报告中介绍的知名公司。这些公司专注于开发新技术、升级现有产品并扩大其地域分布,以满足全球不断增长的消费者需求。
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
This text is related
to segments covered.
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market, by end user, is categorized into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest gallium-68 market share in 2022 and it is anticipated to register the highest CAGR during the forecast period.
The gallium-68 market is expected to be valued at US$ 1.070.34 million in 2030.
By application, the market is segmented into oncology, neurology, cardiology, and others. The oncology segment held the largest gallium-68 market share in 2022 and it is anticipated to register the highest CAGR during the forecast period. Based on oncology the market is subsegmented into prostate cancer, neuroendocrine tumors, and others.
The gallium-68 market was valued at US$ 782.36 million in 2022.
The gallium-68 market majorly consists of the players, including Novartis AG, Telix Pharmaceuticals (US) Inc, IRE-ELiT SA, ITM Medical Isotopes GmbH, Eckert & Ziegler Radiopharma GmbH, ARTMS Inc, IBA Radiopharma Solutions, Cardinal Health, Rosatom, and Evergreen Theragnostics Inc.
Gallium-68 is a positron-emitting radioisotope used in medical diagnostic procedures produced from germanium-68/gallium-68 (68Ge/68Ga) generator. Gallium-68 has good positron-emitting properties and a half-life of 68 min.
Factors such as increase in the prevalence of prostate cancer and neuroendocrine tumors and the increasing use of nuclear imaging techniques propel the gallium-68 market growth.
The List of Companies - Gallium-68 Market
- Novartis AG
- Telix Pharmaceuticals (US) Inc
- IRE-ELiT SA
- ITM Medical Isotopes GmbH
- Eckert & Ziegler Radiopharma GmbH
- ARTMS Inc
- IBA Radiopharma Solutions
- Cardinal Health
- Rosatom
- Evergreen Theragnostics Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.